Journal Management System
 
Home  |   Add your Journal  |   Features  |   Journal List
Author Login | Reviewer Login | Editor Login
Search  

Medical Archives
Periodical of AVICENA, d.o.o., Sarajevo
Journal Home Page
ISSN: 0350-199X (Print)
ISSN: 1986-5961 (Online)
Language: [ English ]  
News / Announcements

  » Volume 68, Issue 5
      pp. 300-363
  » Volume 68, Issue 4
      pp. 228-293
  » Volume 68, Issue 3
      pp. 156-222
  » Volume 68, Issue 2
      pp. 76-146
  » Volume 68, Issue 1
      pp. 4-70

 

Open Access

Original Research



The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes

Zelija Velija-Asimi, Sebija Izetbegovic, Jasenko Karamehic, Jozo Coric, Mirsad Panjeta, Amra Macic-Dzankovic, Jasminka Djelilovic-Vranic, mela Dizdarevic-Bostandzic.

Abstract
Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of antihyperglycemic drugs that block degradation of incretin hormones. Goal: To assess the effects of treatment with DPP-4 inhibitors on glucoregulation and body weight in obese patients with type 2 diabetes mellitus. Patients and methods: The study included 9 females and 9 males with type 2 diabetes (n=18), BMI=31.24±2,26 kg/m2, mean age 58 ±6,8 years. The patients have been thoroughly evaluated before treatment, and 6 months after treatment with DPP-4 inhibitor (sitagliptin) in combination with metformin. Results: After 6 months of treatment with DPP-4 inhibitors in combination with metformin HbAlc (-1,49%)., FBG (-3.75 mmol/L) and PBG (-5.79 mmol/L) significantly reduced (p=0.000). Mean body weight also significantly reduced (-12.5%; p=0.000). Reduction of mean fasting insulin was 5.46 mIU/L or 27% (p=0.000). Mean HOMA-IR change was −1.64 (p=0.000). Also there was significant decreasing of systolic blood pressure (p=0.001), cholesterol (p=0.004), triglycerides (p=0.001), LDL (p=0.002) and increasing of HDL (p=0.002). Hypoglycaemia was not registered in any of the patients. Conclusion: These results show that in obese patients with type 2 diabetes, DPP-4 inhibitors treatment in combination with metformin was associated with improvements in glycaemic control, and a reduction in body weight.

Key words: Dipeptidyl peptidase-4 inhibitors, metformin, type 2 diabetes, obesity.



REFERENCES
1. Kalra S. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes. J Assoc Physicians India. 2011; 59: 237-245.
 
2. Hollander PA, Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med. 2010; 122(3): 71-80. http://dx.doi.org/10.3810/pgm.2010.05.2144   [Pubmed]       
 
3. Wirth A. Anti-diabetic drugs. Weight reduction as a favourable side effect. Internist (Berl). 2011; 52(4): 451-461.
 
4. Cornell S. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. J Clin Pharm Ther. 2012; 37(5): 510-524. http://dx.doi.org/10.1111/j.1365-2710.2012.01342.x   [Pubmed]       
 
5. Solun B, Marcoviciu D, Dicker D. Dipeptidyl peptidase-4 inhibitors and their effects on the cardiovascular system. Curr Cardiol Rep. 2013; 15(8): 382. http://dx.doi.org/10.1007/s11886-013-0382-2   [Pubmed]       
 
6. Scheen AJ. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgrad Med. 2013; 125(3): 7-20. http://dx.doi.org/10.3810/pgm.2013.05.2659   [Pubmed]       
 
7. De Fronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab. 2012; 97(5): 1615-1622. http://dx.doi.org/10.1210/jc.2011-2243   [Pubmed]       
 

How to Cite this Article
Pubmed Style

Velija-Asimi Z, Izetbegovic S, Karamehic J, Coric J, Panjeta M, Macic-Dzankovic A, Djelilovic-Vranic J, . The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes . Med Arh. 2013; 67(5): 365-367. doi:10.5455/medarh.2013.67.365-367



Web Style

Velija-Asimi Z, Izetbegovic S, Karamehic J, Coric J, Panjeta M, Macic-Dzankovic A, Djelilovic-Vranic J, . The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes . www.scopemed.org/?mno=46177 [Access: October 22, 2014]. doi:10.5455/medarh.2013.67.365-367



AMA (American Medical Association) Style

Velija-Asimi Z, Izetbegovic S, Karamehic J, Coric J, Panjeta M, Macic-Dzankovic A, Djelilovic-Vranic J, . The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes . Med Arh. 2013; 67(5): 365-367. doi:10.5455/medarh.2013.67.365-367



Vancouver/ICMJE Style

Velija-Asimi Z, Izetbegovic S, Karamehic J, Coric J, Panjeta M, Macic-Dzankovic A, Djelilovic-Vranic J, . The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes . Med Arh. (2013), [cited October 22, 2014]; 67(5): 365-367. doi:10.5455/medarh.2013.67.365-367



Harvard Style

Velija-Asimi, Z., Izetbegovic, S., Karamehic, J., Coric, J., Panjeta, M., Macic-Dzankovic, A., Djelilovic-Vranic, J. & (2013) The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes . Med Arh, 67 (5), 365-367. doi:10.5455/medarh.2013.67.365-367



Turabian Style

Velija-Asimi, Zelija, Sebija Izetbegovic, Jasenko Karamehic, Jozo Coric, Mirsad Panjeta, Amra Macic-Dzankovic, Jasminka Djelilovic-Vranic, and mela Dizdarevic-Bostandzic. 2013. The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes . Medical Archives, 67 (5), 365-367. doi:10.5455/medarh.2013.67.365-367



Chicago Style

Velija-Asimi, Zelija, Sebija Izetbegovic, Jasenko Karamehic, Jozo Coric, Mirsad Panjeta, Amra Macic-Dzankovic, Jasminka Djelilovic-Vranic, and mela Dizdarevic-Bostandzic. "The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes ." Medical Archives 67 (2013), 365-367. doi:10.5455/medarh.2013.67.365-367



MLA (The Modern Language Association) Style

Velija-Asimi, Zelija, Sebija Izetbegovic, Jasenko Karamehic, Jozo Coric, Mirsad Panjeta, Amra Macic-Dzankovic, Jasminka Djelilovic-Vranic, and mela Dizdarevic-Bostandzic. "The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes ." Medical Archives 67.5 (2013), 365-367. Print. doi:10.5455/medarh.2013.67.365-367



APA (American Psychological Association) Style

Velija-Asimi, Z., Izetbegovic, S., Karamehic, J., Coric, J., Panjeta, M., Macic-Dzankovic, A., Djelilovic-Vranic, J. & (2013) The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes . Medical Archives, 67 (5), 365-367. doi:10.5455/medarh.2013.67.365-367



Submit your manuscript
Register
Abstracting & Indexing
Instructions for Authors
Editorial Board
Aims & Scope
About this Journal
Sign up for TOC

ARTICLE TOOLS
Abstract
PDF Fulltext
Print this article Print this Article
How to cite this articleHow to cite this article
Export to
Export to
Related Records
 Articles by Zelija Velija-Asimi
Articles by Sebija Izetbegovic
Articles by Jasenko Karamehic
Articles by Jozo Coric
Articles by Mirsad Panjeta
Articles by Amra Macic-Dzankovic
Articles by Jasminka Djelilovic-Vranic
Articles by mela Dizdarevic-Bostandzic
on IndexScholar Fulltext
on Google
on Google Scholar
Article Statistics
 Viewed: 849
Downloaded: 190
Cited: 0




 




» For Authors




Become Reviewer


» Login Area






Follow ScopeMed on Twitter

ScopeMed Home
Job Opportunities/Service Offers
About ScopeMed
Terms & Conditions
Privacy Policy
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Service of SAGEYA Publishing for Scientific Publications. Copyright © ScopeMed® International Medical Journal Management and Indexing System.